The use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. [PMID: 19410716]. Here, EGFR is linked to non-small cell lung carcinoma.